Author

Jianzhen Lin

Jiangsu Province Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:spatial transcriptomics· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Bin XiaoiD· 1 shared C. Robson Simon· 1 shared Chenghai Xue· 1 shared Chengpei Zhu· 1 shared Fangze Qian· 1 shared Gao WentaoiD· 1 shared Haitao Zhao· 1 shared Han LiangiD· 1 shared

Activity by Year

2016-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bin XiaoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Co-evolution of Oncogenic KRAS Signaling and LILRBhigh Macrophages Drives Pancreatic Cancer Recurrence

Jianzhen Lin, Zhenzhen Xun, Fangze Qian, Zhigao Chen, Weikang Hu, W. Liu, Yang Wu, Hao Yuan, Lingdi Yin, Yuxing Wang, Xiao Huang, Yujia Dang, Bin Xiao, Junli Wu, Gao Wentao, , Han Liang

This study identifies a co-evolved tumor-immune interaction involving KRAS signaling and LILRBhigh macrophages that drives PDAC recurrence and presents a therapeutic strategy targeting this axis.

bioRxiv · Mar 7, 2026 · PreprintCancer Biology

The landscape of gene fusions in hepatocellular carcinoma

Chengpei Zhu, Yanling Lv, Liangcai Wu, Jinxia Guan, Xue Bai, Jianzhen Lin, Tingting Liu, Zhang Haohai, Wang Anqiang, Xie Yuan, Wan Xueshuai, Zheng Yongchang, Yang Xiaobo, Miao Ruoyu, C. Robson Simon, , Haitao Zhao

This study identifies gene fusions in hepatocellular carcinoma (HCC) using RNA sequencing and validation, finding 43 recurrent fusions with three annotated as disease-related and 19 novel fusions, including potential therapeutic biomarkers.

bioRxiv · May 25, 2016 · PreprintCancer Biology